Abstract 59P
Background
BC is a heterogeneous disease with variable clinical outcomes among patients with the same clinical and pathological characteristics, treated with similar treatment. Despite significant improvement in the outcomes, many of them acquire resistance to multiple anticancer drugs, leading to recurrence and /or metastasis. It remains an unmet need to identify robust molecular defects and novel biomarkers to adopt individualized treatment decisions in BC. CGP using next generation sequencing (NGS) provides more druggable gene aberrations at “one go” that includes somatic BRCA (sBRCA), homologous recombinant repair pathway alteration (HRR) and tumor agnostic markers like tumor mutation burden (TMB) and microsatellite instability (MSI) burden.
Methods
140 BC cases at HCG cancer centre were profiled using Illumina TruSight Oncology 500 assay on a NextSeq2000 in an IRB-approved study. The findings from NGS data were discussed in the molecular tumor board (MTB) and recommendations were documented for change in clinical management and follow-up.
Results
Clinically relevant variants were detected in 133/140 BC patients (95%) with actionable mutations in >80% cases with direct impact on therapy and constituted of 47% Tier 1 and 41% Tier 2 mutations. CGP revealed a multitude of genomic alterations such as PI3KCA/AKT/PTEN signalling pathway (32%) in HR+Her2- mBC and ESR1 mutation (7%) in HR+ mBC predictive of resistance to anti-Her2 and endocrine therapy respectively. 22 patients (16%) with sBRCA and HRR pathways alteration treated either with platinum / PARP inhibitors post platinum treatment were found to have partial-to-complete pathological response (pCR). 23 BC patients with high TMB (16%) were initiated on immunotherapy as a single drug or in combination with chemotherapy and are on follow up. The mutation spectrum, HRR pathway alterations and high TMB of triple- negative BC (TNBC) cases revealed a distinctive mutational profile with clinical utility in >95% cases.
Conclusions
Recommending CGP tests at a more appropriate time helps in modifying BC treatment protocol, clinical decisions and provides patients with greater benefit from targeted treatments based on their specific gene alterations and resistance mechanism.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B.S. Ajaikumar: Financial Interests, Personal and Institutional, Member of Board of Directors, Executive Chairman: HCG. All other authors have declared no conflicts of interest.
Resources from the same session
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract